11 completed, 2 recruiting, 2 terminated, 2 unknown. 18 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 11, Recruiting 2, Terminated 2, Unknown 2, Not yet recruiting 1 |
| Phase 2 | 5 | Completed 4, Not yet recruiting 1 |
Follow Allergic Rhinoconjunctivitis: new trials by email Literature Review of Allergic Rhinoconjunctivitis trials Research Report on Allergic Rhinoconjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063. EP-088_MM09, Placebo - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 3 | Recruiting | Inmunotek S.L. | 250 | 2026-04-15 | 2026-10-29 |
| Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063. EP-088_MM09, Placebo - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 3 | Recruiting | Inmunotek S.L. | 250 | 2026-02-24 | 2026-10-29 |
| A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 HDM SLIT-tablet (12 SQ-HDM), Placebo - Allergic Rhinoconjunctivitis, Allergic Rhinitis | Phase 3 | Completed | ALK-Abelló A/S | 327 | 2025-09-01 | 2026-10-05 |
| Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract 3,000 MM09, 9,000 MM09, Placebo sublingual - Allergic Rhinitis, Allergic Asthma | Phase 2 / Phase 3 | Not yet recruiting | Inmunotek S.L. | 90 | 2023-11-01 | 2023-10-23 |
| Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma STALORAL® Birch 300 IR - Allergic Rhinoconjunctivitis, Birch Pollen Allergy | Phase 3 | Completed | Stallergenes Greer | 553 | 2023-09-20 | 2025-11-26 |
| Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL) - House Dust Mite Allergy, Perennial Allergic Rhinitis | Phase 3 | Unknown | Inmunotek S.L. | 400 | 2022-12-01 | 2022-11-18 |
| Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000) - Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis | Phase 3 | Terminated | Inmunotek S.L. | 18 | 2021-04-30 | 2023-12-19 |
| Adolescent Mite Allergy Safety Evaluation HDM SLIT-tablet - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 3 | Completed | ALK-Abelló A/S | 253 | 2020-09-23 | 2023-07-03 |
| A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber Sublingual allergy immunological tablet, Placebo - Allergic Rhinoconjunctivitis | Phase 3 | Terminated | ALK-Abelló A/S | 80 | 2019-11-04 | 2022-06-30 |
| Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch Depiquick Birch (DPG103), Placebo - Allergic Rhinoconjunctivitis | Phase 3 | Completed | Novartis | 202 | 2012-03-01 | 2017-03-22 |
| Avanz Phleum Pratense Maintenance Dose Avanz Phleum pratense, Placebo - Allergic Rhinoconjunctivitis | Phase 2 / Phase 3 | Completed | ALK-Abelló A/S | 450 | 2011-09-01 | 2014-01-22 |
| An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy AVANZ Phleum pratense - Allergic Rhinoconjunctivitis | Phase 2 / Phase 3 | Completed | ALK-Abelló A/S | 199 | 2011-06-01 | 2015-03-06 |
| A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis Oralgen, placebo control - Allergic Rhinoconjunctivitis | Phase 3 | Unknown | Artu Biologicals | 374 | 2008-12-01 | 2010-04-30 |
| A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine Grazax + Aerius, Grazax + placebo - Allergic Rhinoconjunctivitis | Phase 3 | Completed | ALK-Abelló A/S | 46 | 2008-09-01 | 2013-02-08 |
| Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children Grass pollen allergens in a water/glycerol solution, Placebo - Allergic Rhinoconjunctivitis | Phase 3 | Completed | Allergopharma GmbH & Co. KG | 207 | 2008-02-01 | 2015-10-16 |
| Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica Depigoid Parietaria judaica 1000DPP/ml, Placebo - Allergic Rhinoconjunctivitis | Phase 3 | Completed | Laboratorios Leti, S.L. | 153 | 2008-02-01 | 2013-11-11 |
| Long-term Efficacy and Safety Study With Oralgen Grass Pollen Oralgen, placebo - Allergic Rhinoconjunctivitis | Phase 2 / Phase 3 | Completed | Artu Biologicals | 356 | 2007-08-01 | 2010-05-05 |
| Efficacy and Safety of Grass Pollen Sublingual Immunotherapy Oralgen, grass pollen extract - Allergic Rhinoconjunctivitis | Phase 2 / Phase 3 | Completed | Artu Biologicals | 605 | 2006-12-01 | 2010-05-05 |
Hypersensitivity (6) · Rhinitis, Allergic (6) · Dust Mite Allergy (3) · Rhinitis, Allergic, Perennial (2) · Conjunctivitis, Allergic (1) · Rhinitis (1) · Rhinitis, Allergic, Seasonal (1)
Immune System Diseases (11) · Hypersensitivity, Immediate (8) · Nose Diseases (8) · Otorhinolaryngologic Diseases (8) · Respiratory Hypersensitivity (8) · Respiratory Tract Diseases (8) · Rhinitis (7) · Hypersensitivity (5) · Rhinitis, Allergic (2) · Conjunctival Diseases (1) · Conjunctivitis (1) · Eye Diseases (1) · Infections (1) · Respiratory Tract Infections (1) · Rhinitis, Allergic, Perennial (1)
grass pollen extract, alum-adsorbed (2) · Grazax (1) · desloratadine (1)
ALK-Abelló A/S (6) · Inmunotek S.L. (5) · Artu Biologicals (3) · Allergopharma GmbH & Co. KG (1) · Laboratorios Leti, S.L. (1) · Novartis (1) · Stallergenes Greer (1)
Germany (9) · Spain (6) · Slovakia (4) · Bulgaria (3) · Czechia (3) · Hungary (3) · Lithuania (3) · Netherlands (3) · Austria (2) · China (2) · France (2) · Poland (2) · Portugal (2) · Argentina (1) · Belgium (1)
Ana Isabel Tabar Purroy, MD. PhD (1) · Ana Isabel Tabar Purroy, MD; PhD (1) · Andreas Horn, MD (1) · Angel Ferrer, Dr (1) · Dyonne van Duren, MD, PhD (1) · Folkert R Roossien (1) · Folkert Roossien (1) · Iveta Kozlovska, MD, PhD (1) · Jorge Fernando Maspero, MD, PhD (1) · Knut Schaekel, MD, PhD (1) · Luo Zhang, Prof. (1) · Miguel Tortajada (1)
2018 (1), 2025 (1)